The SEC’s complaint alleges the company’s investors were misled about product testing and cybersecurity, and its CEO’s previous criminal history.
SA 1933 Rule 17(a)(2)
Disciplinary decisions issued December 6 – 12, 2025.
The broker-dealer’s conduct was found to violate Section 17(a)(2) of the Securities Act.
The SEC found fault with the firm for how it reported cardiovascular safety results to investors regarding its drug, Roxadustat.
The SEC has recently closed three very different but equally brazen fraud cases, each a window into a distinct form of financial misconduct.
Elanco’s use of sales incentives created misleading impressions of customer demand, the SEC stated.
Five SEC enforcement actions include allegations that some advisers’ recommendations were not in the best interest of clients.
The four settlements come nearly one year after the SEC sued SolarWinds for misleading investors about its cybersecurity controls.